Vertex Pharmaceuticals Incorporated (VRTX) Analysts See $0.05 EPS

July 18, 2017 - By Vivian Currie

 Vertex Pharmaceuticals Incorporated (VRTX) Analysts See $0.05 EPS
Investors sentiment decreased to 0.88 in 2016 Q4. Its down 0.22, from 1.1 in 2016Q3. It is negative, as 48 investors sold Vertex Pharmaceuticals Incorporated shares while 165 reduced holdings. 46 funds opened positions while 141 raised stakes. 232.42 million shares or 0.81% less from 234.32 million shares in 2016Q3 were reported.
Henderson Gru Public Ltd Co owns 34,769 shares or 0.02% of their US portfolio. Raymond James Services invested 0% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Teachers Retirement Of The State Of Kentucky holds 114,150 shares or 0.11% of its portfolio. American Century Cos Inc holds 289,974 shares. Adirondack Com reported 230 shares or 0.01% of all its holdings. The California-based National Planning has invested 0.03% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Jane Street Grp Ltd Limited Liability Company has 0.02% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 68,528 shares. Metropolitan Life Insur Company owns 134,407 shares or 0.07% of their US portfolio. Princeton Cap Mgmt Inc accumulated 1.17% or 23,796 shares. Camarda Advsrs Ltd accumulated 20 shares. Veritable Limited Partnership has 0.01% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vanguard Group invested 0.07% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). State Of New Jersey Common Pension Fund D, a New Jersey-based fund reported 260,000 shares. Blair William Com Il, a Illinois-based fund reported 6,121 shares. Moreover, Hsbc Public Ltd Co has 0.02% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 127,284 shares.

Since February 1, 2017, it had 0 insider buys, and 30 sales for $68.81 million activity. $179,434 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Silva Paul M on Wednesday, March 29. $900,000 worth of stock was sold by ALTSHULER DAVID on Friday, April 28. Chodakewitz Jeffrey also sold $654,015 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares. 1,176 shares were sold by Bhatia Sangeeta N., worth $151,045. Shares for $12.22M were sold by SMITH IAN F. Arbuckle Stuart A sold $3.38M worth of stock.

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on July, 26. They expect $0.05 EPS, up 600.00 % or $0.06 from last year’s $-0.01 per share. VRTX’s profit will be $12.46M for 646.05 P/E if the $0.05 EPS becomes a reality. After $0.13 actual EPS reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -61.54 % negative EPS growth. The stock decreased 1.36% or $1.78 during the last trading session, reaching $129.21. About 1.14 million shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since July 18, 2016 and is uptrending. It has outperformed by 28.99% the S&P500.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 19 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 12 have Buy rating, 0 Sell and 7 Hold. Therefore 63% are positive. Vertex Pharmaceuticals had 43 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by Argus Research with “Buy” on Thursday, February 4. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Buy” rating given on Friday, June 23 by Needham. The company was downgraded on Thursday, April 28 by Goldman Sachs. The firm earned “Outperform” rating on Tuesday, March 8 by Leerink Swann. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Outperform” rating by Credit Suisse on Wednesday, January 20. The firm has “Market Perform” rating by William Blair given on Tuesday, November 1. Stifel Nicolaus maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Thursday, January 26. Stifel Nicolaus has “Buy” rating and $100 target. The firm has “Buy” rating given on Sunday, July 9 by Oppenheimer. As per Monday, October 24, the company rating was downgraded by H.C. Wainwright. H.C. Wainwright upgraded Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Friday, October 30 to “Buy” rating.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The company has market cap of $32.20 billion. The Firm is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs in other indications. It has a 182.48 P/E ratio. The Company’s marketed medicines are ORKAMBI and KALYDECO.

More news for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were recently published by: Streetinsider.com, which released: “Vertex Pharma (VRTX) Reports Reimbursement Agreement in Italy for ORKAMBI …” on July 13, 2017. Benzinga.com‘s article titled: “2 Reasons Vertex Pharmaceuticals Just Got Upgraded” and published on June 23, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.